Lynparza (AstraZeneca Pharmaceuticals LP)


Welcome to the PulseAid listing for the Lynparza drug offered from AstraZeneca Pharmaceuticals LP. This Poly(ADP-Ribose) Polymerase Inhibitor [EPC],Poly(ADP-Ribose) Polymerase Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: AstraZeneca Pharmaceuticals LP
NON-PROPRIETARY NAME: olaparib
SUBSTANCE NAME: OLAPARIB
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Poly(ADP-Ribose) Polymerase Inhibitor [EPC],Poly(ADP-Ribose) Polymerase Inhibitors [MoA]
ROUTE: ORAL
DOSAGE FORM: TABLET, FILM COATED
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2017-08-17
END MARKETING DATE: 0000-00-00


Lynparza HUMAN PRESCRIPTION DRUG Details:

Item DescriptionLynparza from AstraZeneca Pharmaceuticals LP
LABELER NAME: AstraZeneca Pharmaceuticals LP
DEA SCHEDULE:
ACTIVE STRENGTH: 100(mg/1)
START MARKETING DATE: 2017-08-17
END MARKETING DATE: 0000-00-00
PRODUCT ID: 0310-0668_fa29d621-06df-44fb-a406-148333cdb25c
PRODUCT NDC: 0310-0668
APPLICATION NUMBER: NDA208558

Other OLAPARIB Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
AstraZeneca Pharmaceuticals LPLynparza